Acute respiratory distress syndrome (ARDS) has been a
life threat
for patients in ICUs. Vast efforts have been devoted, while no medication
has proved viable, which may be ascribed to inadequate drug delivery
to damaged tissues and insufficient control of lung inflammation.
Given the anti-inflammatory role of M2-type macrophages, M2 macrophage-derived
nanovesicles and lung-targeting liposomes are cofused to fabricate
hybrid liposomes–nanovesicles (LNVs). Benefiting from the incorporated
lung-homing moiety, LNVs demonstrate high pulmonary accumulation with
a lung/liver ratio of 14.9, which is approximately 53.3-fold of free
nanovesicles. Thus, M2 macrophage-derived nanovesicles can be delivered
to lung tissues for executing immunoregulatory functions. LNVs display
phagocytosis by the infiltrated neutrophils and macrophages, exhibiting
sustained release of preloaded IKK-2 inhibitor (TPCA-1). The integrated
nanosystems demonstrate multidimensional suppression of the overwhelming
inflammation, such as decreasing infiltration of inflammatory cells,
achieving restraint on cytokine storms and alleviating oxidative stress.
Therefore, the improved therapeutic outcome in ARDS mice is obtained.
Altogether, the hybrid nanoplatform provides a versatile drug delivery
paradigm for integrating biological nanovesicles and therapeutic molecules
by cofusion of nanovesicles with liposomes, improving lung biodistribution
and accomplishing a boosted anti-inflammatory response for ARDS therapy.